Ardelyx

ARDX

市值 US$7.98億

New York, New York--(Newsfile Corp. - October 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"), of the important November 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ardelyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

LOS ANGELES, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ARDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardelyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ardelyx between January 13, 2025 and August 6, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) and reminds investors of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

New York, New York--(Newsfile Corp. - October 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"), of the important November 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ardelyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

New York, New York--(Newsfile Corp. - October 15, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) on behalf of investors that purchased or otherwise acquired Ardelyx common stock between January 13, 2025 and August 6, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Ardelyx and have suffered losses, you may CLICK HERE to contact us.

New class action for Ardelyx, Inc. (ARDX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/16/2026

Promise vs. Reality: Ardelyx pointed investors toward $1.75 billion in combined peak sales for IBSRELA and XPHOZAH, while the complaint alleges payer utilization-management barriers were already restricting patient access before the Company cut 2026 guidance and withdrew its long-term XPHOZAH target.

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

New York, New York--(Newsfile Corp. - October 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"), of the important November 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ardelyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Ardelyx, Inc. (NASDAQ: ARDX) common stock between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"). Ardelyx, Inc. develops and commercializes medicines, including IBSRELA for the treatment of irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adults with chronic kidney disease on dialysis.